AGA技术综述:中重度腔道及肛周瘘管型克罗恩病的药物治疗
该技术综述基于GRADE框架,针对成人中重度腔道型及瘘管型克罗恩病门诊患者,评估不同药物诱导和维持缓解的疗效与安全性、单药与联合治疗比较、升阶梯与降阶梯策略以及激素和美沙拉秦的作用。综述旨在为AGA临床指南更新提供证据基础。
要点
- 中重度克罗恩病需免疫调节剂和/或生物制剂治疗以降低手术、住院和感染风险。
- 比较不同药物疗效和安全性的证据有限,导致临床实践差异大。
- 自2013年指南以来,维得利珠单抗和乌司奴单抗两种新生物制剂获批。
核心结论
- 中重度克罗恩病的 optimal 药物治疗决策复杂,需权衡疗效与安全性。
研究设计与样本
- 按照GRADE框架完成的技术综述,针对成人中重度腔道型和瘘管型克罗恩病门诊患者。
主要发现
- 中重度克罗恩病患者需手术、住院和发生并发症的风险高。
- 免疫调节剂和/或生物制剂(包括TNF-α拮抗剂、维得利珠单抗、乌司奴单抗)单用或联合免疫调节剂可降低上述风险。
- 不同治疗方案的比较疗效和安全性证据有限,导致实践差异。
关键数值与推荐
- 综述聚焦于不同药物诱导和维持缓解的总体及比较疗效(有无既往TNF-α拮抗剂暴露)。
- 比较生物制剂单药与联合免疫调节剂的疗效和安全性。
- 比较降阶梯( upfront 生物制剂和/或免疫调节剂)与升阶梯(美沙拉秦失败后加速使用生物制剂和/或免疫调节剂)策略。
- 评估激素和美沙拉秦在诱导和/或维持缓解中的作用。
- 针对瘘管型克罗恩病,评估药物干预实现瘘管愈合的疗效及无明确活动性感染时辅助抗生素的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The incidence and prevalence of Crohn's disease (CD) is rising globally. Patients with moderate to severe CD are at high risk for needing surgery and hospitalization and for developing disease-related complications, corticosteroid dependence, and serious infections. Optimal management of outpatients with moderate to severe luminal and/or fistulizing (including perianal) CD often requires the use of immunomodulator (thiopurines, methotrexate) and/or biologic therapies, including tumor necrosis factor-α antagonists, vedolizumab, or ustekinumab, either as monotherapy or in combination (with immunomodulators) to mitigate these risks. Decisions about optimal drug therapy in moderate to severe CD are complex, with limited guidance on comparative efficacy and safety of different treatments, leading to considerable practice variability. Since the last iteration of these guidelines published in 2013, significant advances have been made in the field, including the regulatory approval of 2 new biologic agents, vedolizumab and ustekinumab. Therefore, the American Gastroenterological Association prioritized updating clinical guidelines on this topic. To inform the clinical guidelines, this technical review was completed in accordance with the GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework. The review addressed the following focused questions (in adult outpatients with moderate to severe luminal CD): overall and comparative efficacy of different medications for induction and maintenance of remission in patients with or without prior exposure to tumor necrosis factor-α antagonists, comparative efficacy and safety of biologic monotherapy vs combination therapy with immunomodulators, comparative efficacy of a top-down (upfront use of biologics and/or immunomodulator therapy) vs step-up treatment strategy (acceleration to biologic and/or immunomodulator therapy only after failure of mesalamine), and the role of corticosteroids and mesalamine for induction and/or maintenance of remission. Finally, in adult outpatients with moderate to severe fistulizing CD, this review addressed the efficacy of pharmacologic interventions for achieving fistula and the role of adjunctive antibiotics without clear evidence of active infection.
引用
- Singh S, Proctor D, Scott FI, et al. AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. Gastroenterology. 2021. PMID: 34051985. doi:10.1053/j.gastro.2021.04.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。